UA129500U - METHOD OF FORECASTING OSTEOARTHrosis DEVELOPMENT - Google Patents

Abstract

A method for predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, serum polymorphism of methylenetetrahydrofolate reductase (MTHFR C677T), nitric oxide synthase (eNOS T786C), oxyprolin content, homocysteine, and interleukin 6 (IL-6) are determined. With homozygous carrier 677-TT, 786-SS and oxyproline levels> 15 μmol / l, homocysteine> 20 μmol / l, IL-6> 10 ng / l predict the development of osteoarthrosis.

Description

The proposed useful model The method of predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (Okorokov

A.N. Diagnosis of diseases of internal organs. - T. 2. - M.: Med. lit., 2001. - pp. 186-196).

The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The set task is solved by the fact that, in addition to clinical examination and radiography, polymorphism of methylenetetrahydrofolate reductase genes (MTNEV) is determined in the patient's blood serum

Сб677Т), nitric oxide synthase (ЕМО5 T786С), content of oxyproline, homocysteine, interleukin 6 (IL-6). With homozygous carriers of 677-TT, 786-SS, levels of oxyproline 215 μmol/l, homocysteine »20 μmol/l, IL-6 210 ng/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the polymorphism of MTNEV C677T, eMmo5 T786C genes is determined, the content of oxyproline, homocysteine, and IL-6 is determined by the immunoenzymatic method. With homozygous carrier 677-HT, 786-SS, levels of oxyproline 215 μmol/l, homocysteine 220 μmol/l, IL-b »10 ng/l predict the development of osteoarthritis.

A specific example of using the method

Patient S., 58 years old, was hospitalized in the clinic due to pain syndrome in the right hip joint. Examined, x-ray taken. No signs of osteoarthritis were found. The polymorphism of MTNEV C677T and eMmo5 17860 genes was determined in blood serum. The content of oxyproline, homocysteine, IL-6 was determined by immunoenzymatic method. A homozygous carrier of 677-TT and 786-SS was established, the levels of oxyproline - 29 μmol/l, homocysteine - 33 μmol/l, IL-6-22 ng/l.

The development of osteoarthritis was diagnosed. After 13 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that, in addition, polymorphisms of the genes methylenetetrahydrofolate reductase (MTNEV C677T), nitric oxide synthase (6ЭМО5 17860), the content of oxyproline, homocysteine, interleukin 6 (IL-6) are determined in the blood serum , and with homozygous carriers of 677-TT, 786-SS and levels of oxyproline <15 μmol/l, homocysteine 220 μmol/l, IL-b6 »10 ng/l predict the development of osteoarthritis.